Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011849 (
diabetes
)
277,896
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Type 2
diabetes
osteoporosis has recently become a hot topic in the study of diabetic complications, but the specific mechanism of its development remains unclear.
Non-imprinted in Prader-Willi/Angelman syndrome region protein 2
(
NIPA2
), a highly-selective magnesium ion transporter, has been found to be associated with type 2 diabetes. In this study we aimed to investigate the specific role and mechanism of
NIPA2
in the pathogenesis of type 2 diabetes osteoporosis. We first used western blotting, PCR, immunofluorescence, and magnesium ion probes to detect changes of
NIPA2
and intracellular magnesium levels in osteoblasts at different concentrations of advanced glycation end products (AGEs). We then up- or down-regulated
NIPA2
using a lentivirus and analyzed apoptotic biomarkers as well as the osteogenic ability of osteoblasts. We found that AGEs dose-dependently down-regulated the expression of
NIPA2
in osteoblasts.
NIPA2
also regulated osteoblast apoptosis by affecting the intracellular magnesium level and further affecting the osteogenic capacity of osteoblasts. Our study revealed the changes of
NIPA2
in response to AGEs in the environment, as well as its function and mechanism in osteoblasts, demonstrating its important role in the pathogenesis of type 2 diabetes osteoporosis. The study suggests that
NIPA2
is a potential target for the treatment of type 2 diabetes osteoporosis.
...
PMID:NIPA2 regulates osteoblast function via its effect on apoptosis pathways in type 2 diabetes osteoporosis. 3100 74
